At a Glance
Prostate cancer treatment regret is common, but often preventable. It usually stems from unexpected side effects or feeling rushed — not from the treatment “failing.” Thorough diagnosis with MRI and targeted biopsy, honest counselling about trade-offs, and properly exploring every suitable option — including active surveillance and, for selected men, focal therapy — give men the best chance of a decision they can live with.[3,8]
Key Takeaways
- Regret is often preventable — it’s usually linked to unexpected side effects, poor communication, and limited involvement in the decision.[3,8]
- Function matters most — the common regrets relate to sexual function, urinary control, bowel symptoms, and loss of ejaculation.
- Low-risk cancer may not need immediate treatment — active surveillance is often the preferred approach when it is safe and appropriate.[5]
- Better diagnosis helps — MRI and targeted biopsy help separate cancers that need treating from those that can be monitored.[5]
- Focal therapy is an option for selected men — it aims to treat the significant cancer while sparing surrounding structures, but still needs careful selection and follow-up.[4,7]
- A second opinion can clarify — a specialist team can help you understand whether surveillance, focal therapy, surgery, or radiotherapy fits best.
A diagnosis of localised prostate cancer can lead to several possible treatment choices — active surveillance, surgery, radiotherapy, or focal therapy in selected cases. For some men, the hardest part is not only choosing a treatment, but later living with the consequences of that decision.
Treatment regret does not usually mean the cancer treatment “failed.” More often, regret develops when the side effects, recovery, or long-term impact on quality of life were different from what the patient expected. Urinary leakage, erectile dysfunction, bowel symptoms, loss of ejaculation, anxiety about cancer control and its effect on mental wellbeing, and a sense of having been rushed can all contribute.
The aim is not to frighten men away from treatment. It is to make sure the decision is properly informed, proportionate to the cancer risk, and based on what matters most to the individual patient.
Why do some men experience treatment regret?
Treatment regret usually develops when there is a mismatch between what a patient expected and what happened after treatment.
This can include:
- side effects that were more troublesome than expected
- a slower or more difficult recovery than anticipated
- feeling that the decision was rushed
- not understanding the long-term effects on erections, continence, ejaculation, or bowel function
- later discovering that active surveillance or a less invasive approach may have been reasonable
- feeling that the treatment decision was made for the patient rather than with them
Regret is not always immediate. Some men feel satisfied at first because the cancer has been treated, but later struggle with the day-to-day impact of treatment side effects. This is particularly relevant in localised prostate cancer, where many men live for many years after diagnosis.
A good treatment decision should therefore consider both cancer control and quality of life. One without the other is only half the conversation.
Common regrets after prostate cancer treatment
The most common regrets after prostate cancer treatment relate to function and quality of life.
These may include:
- losing erectile function
- urinary leakage or the need for pads
- changes in ejaculation or dry orgasm
- bowel urgency, bleeding, or irritation after radiotherapy
- reduced confidence or intimacy
- not asking enough questions before treatment
- not seeking a second opinion
- choosing radical treatment for a cancer that may have been suitable for monitoring
Some men also regret not being told clearly that all treatments involve trade-offs. Surgery, radiotherapy, active surveillance, and focal therapy each have advantages and disadvantages. The ‘best’ option depends on the cancer grade, PSA, MRI findings, biopsy results, prostate size, general health, life expectancy, baseline urinary and sexual function, and patient preference.
Overdiagnosis and overtreatment in prostate cancer
Overdiagnosis means finding a prostate cancer that would never have caused symptoms or shortened life. Overtreatment means treating such a cancer aggressively, exposing the patient to side effects without clear personal benefit.
This matters because some prostate cancers grow slowly. In men with low-risk localised prostate cancer, active surveillance can often delay or avoid treatment while keeping the cancer under close review. Active surveillance is not ‘doing nothing’. It usually involves PSA monitoring, clinical review, repeat MRI, and sometimes repeat biopsy.
For suitable men, this can reduce the risk of unnecessary treatment side effects. If the cancer later shows signs of becoming more significant, curative treatment can still be considered. The key point is risk.
The role of better diagnosis and imaging
Good decision-making begins with accurate diagnosis. Modern prostate cancer assessment commonly includes PSA testing, MRI, and biopsy when indicated. MRI can show suspicious areas within the prostate and help guide biopsy towards the areas most likely to contain clinically significant disease. This can reduce the risk of missing important cancer and may also reduce unnecessary sampling in some situations.
A transperineal prostate biopsy takes samples through the skin between the scrotum and back passage rather than through the rectum. It is now widely used in UK prostate cancer diagnosis and can be performed under local or general anaesthetic depending on the technique and patient factors.
MRI helps locate and risk-stratify suspicious areas. Biopsy provides tissue confirmation and grading. In many men, both are still needed before treatment decisions are made. Better diagnosis does not automatically mean more treatment. In fact, one of its most important roles is identifying men who may safely avoid immediate treatment.
“In my experience, the men who feel most at peace with their decision are those who understood the trade-offs before treatment, not just afterwards. Focal therapy can offer excellent quality-of-life outcomes for carefully selected men — but it’s the accurate diagnosis and honest counselling beforehand that make the real difference.”
— Mr Raj Nigam, Consultant Urological Surgeon (FRCS (Urol), GMC: 3265226)
Can focal therapy reduce the risk of regret?
Focal therapy is a treatment approach for selected men with localised prostate cancer. Instead of treating or removing the whole prostate, it targets the area containing the significant cancer.
The aim is to control the clinically significant tumour while reducing damage to surrounding prostate tissue, nerves, the urinary sphincter, bladder neck, and rectum. Because of this, focal therapy is associated with favourable urinary outcomes in many published series, and may reduce the risk of some side effects compared with whole-gland treatment in appropriately selected men.
However, focal therapy is not suitable for everyone. It may be considered when:
- the cancer is localised within the prostate
- the significant disease can be clearly identified on MRI and biopsy
- the tumour location is technically suitable for treatment
- there is no evidence of disease that clearly requires whole-gland or systemic treatment
- the patient understands the need for follow-up after treatment
Focal therapy does not remove the need for monitoring. PSA, MRI, and sometimes repeat biopsy may still be needed afterwards. Some men may require a second focal treatment, surgery, radiotherapy, or other treatment later. Every discussion should be balanced, therefore. Focal therapy may reduce the burden of side effects for selected men, but it cannot guarantee no subsequent treatment regret.
Comparing the main treatment approaches
| Approach | Main aim | Continence | Sexual function | Typically considered when |
|---|---|---|---|---|
| Active surveillance | Monitor low-risk (or selected favourable intermediate-risk) cancer and treat only if it progresses | Preserved | Preserved | Low-risk, slow-growing disease |
| Radical prostatectomy | Remove the whole prostate and seminal vesicles | 80–95% | 30–70% | Localised disease, fit for surgery |
| Radiotherapy | Treat the whole prostate with radiation, sometimes with hormone therapy | Variable | Variable (± hormone effects) | Localised / locally advanced disease |
| Focal therapy | Treat the significant cancer area while sparing surrounding structures | 97% (FTC audit, n=265) | 90%+ (FTC audit, n=265) | Selected localised, MRI-visible disease |
Sources: FTC one-year outcome audit (n=265); published literature.[1,4,7] Outcomes for surgery and radiotherapy vary by patient and centre.
Every patient at The Focal Therapy Clinic is assessed by an experienced MDT (multidisciplinary team) to ensure the treatment is right for their cancer and personal circumstances. This includes urologists, radiologists, oncologists, and other prostate cancer specialists.
Get Expert Advice & The Latest Research
Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.
Making an informed treatment decision
The best way to reduce future regret is to make the decision slowly, clearly, and with the right information. Useful questions to ask your urologist include:
- What is the grade and stage of the cancer?
- What are the likely effects on erections, continence, ejaculation, bowel function, and daily life?
- What side effects may improve, and which may be long-term?
- What follow-up will be needed after treatment?
- What would happen if the cancer came back or progressed?
- Would a second opinion change the options?
Some men benefit from speaking with a patient advocate like Eva, our patient advocate, who helps others navigate their journey. The important point is not that every man should choose the least invasive option. The important point is that every man should understand the consequences of each realistic option before choosing.
Patient experiences and quality of life after focal therapy
Many men who choose focal therapy do so because they are trying to balance cancer control with quality of life. Published studies suggest that focal therapy can offer favourable urinary outcomes in selected patients, with sexual outcomes varying according to baseline function, tumour location, treatment area, age, and the technology used.
This is particularly relevant for men who are worried about incontinence or erectile dysfunction after whole-gland treatment. Focal therapy can still cause urinary symptoms, erectile changes, discomfort, infection, retention, or the need for further treatment.
The most satisfied patients are usually those who understood the trade-off before treatment: focal therapy aims to reduce treatment burden, not remove risk altogether.
FAQs
A: Some men do. Studies suggest that treatment regret is not rare after localised prostate cancer. It is more likely when men experience troublesome side effects, feel poorly informed, or feel that they were not sufficiently involved in the decision.
Regret does not necessarily mean the treatment was medically wrong. It often means the patient’s expectations did not match the reality of recovery, side effects, or long-term quality of life.
A: Common causes include erectile dysfunction, urinary leakage, bowel symptoms, loss of ejaculation, anxiety about recurrence, and feeling rushed into treatment. Regret can also occur when men later learn that active surveillance or another suitable option was not fully discussed.
A: There is no single answer for every patient. Surgery and radiotherapy can both affect quality of life, but in different ways. Surgery is more closely associated with urinary incontinence and erectile dysfunction, while radiotherapy can affect bowel, urinary, sexual, and hormonal function, especially when combined with hormone therapy.
Studies suggest that regret is strongly linked to functional outcomes and whether the patient felt prepared for those outcomes.
A: It cannot always be avoided, but the risk can be reduced. Men should be given clear information about all suitable options, including active surveillance where appropriate. They should also understand the likely effects of each treatment on urinary, sexual, bowel, and emotional wellbeing.
Shared decision-making, specialist counselling, and second opinions can all help.
A: Focal therapy is designed to treat the significant cancer area while aiming to reduce damage to surrounding structures. In selected men, it is associated with favourable urinary outcomes and may reduce some side effects compared with whole-gland treatment. However, it is not risk-free. Men still need careful selection, counselling, and follow-up.
A: A second opinion can be very helpful, especially if the options are unclear or if only one treatment has been discussed. It may confirm the original recommendation, or it may identify other suitable options such as active surveillance or focal therapy.
References
Al Hussein Al Awamlh, Bashir, et al. ‘Functional Outcomes after Localized Prostate Cancer Treatment.’ JAMA, vol. 331, no. 4, 2024, pp. 302-317.
European Association of Urology. EAU Guidelines on Prostate Cancer. European Association of Urology, 2026.
Fanshawe, Jack B., et al. ‘Decision Regret in Patients with Localised Prostate Cancer: A Systematic Review and Meta-Analysis.’ European Urology Oncology, vol. 6, no. 5, 2023, pp. 456-466.
Guillaumier, Stephanie, et al. ‘A Multicentre Study of 5-Year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.’ European Urology, vol. 74, no. 4, 2018, pp. 422-429.
National Institute for Health and Care Excellence. Prostate Cancer: Diagnosis and Management. NICE Guideline NG131. NICE, 2019, last reviewed 2025.
National Institute for Health and Care Excellence. Focal Therapy Using High-Intensity Focused Ultrasound for Localised Prostate Cancer. HealthTech Guidance 667. NICE, 2023.
Tay, K. J., et al. ‘Established Focal Therapy, HIFU, IRE, or Cryotherapy, Where Are We Now? A Systematic Review and Meta-Analysis.’ Prostate Cancer and Prostatic Diseases, vol. 28, 2025, pp. 693-706.
Wallis, Christopher J. D., et al. ‘Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics with Treatment-Related Regret among Men with Localized Prostate Cancer.’ JAMA Oncology, vol. 8, no. 1, 2022, pp. 50-59.
